Tag:
Achillion Pharmaceuticals
Latest Headlines
Latest Headlines
Achillion burnishes buyout prospects, snags fast track for hep C drug
Achillion CEO Michael Kishbauch hasn't been the least bit shy about touting the company's buyout prospects. Quick to boast about the biotech's promising hepatitis C drugs, he's been raising hopes and stirring buyout buzz with every appearance.
Hep C drug deal frenzy can't be slowed by growing doubts
At the BIO CEO & Investor Conference in New York yesterday, Achillion CEO Michael Kishbauch wrapped up his remarks on the biotech's hepatitis C programs by making it clear that he was angling for
Idenix gets good news on hep C trial, but can't compete with Gilead
Idenix put out the news this morning that the FDA had lifted a partial hold on its hepatitis C drug IDX184--and then watched its share price slide. In a sign of just how volatile the whole hepatitis
Who's next on hep C biotech buyout hit list?
After the big biotech deal comes the big biotech buzz. And one of the big questions on everyone's mind after Gilead Sciences ( $GILD ) announced its $11 billion deal to acquire Pharmasset is, "Who's
Achillion Pharma CEO talks up sale amid Hep C trials
Achillion Pharmaceuticals CEO Michael Kishbauch told Bloomberg that his drug development group has entered serious talks with potential partners and parties interested in buying his company, with the
Venture groups snap up $50M block of Achillion shares
Achillion Pharmaceuticals is raising $50 million through the sale of its common shares to a slate of venture backers in a deal designed to fuel its clinical trial work on new hepatitis C drugs.
Achillion shares spike on promising hep C data
Shares of Achillion Pharmaceuticals jumped 22 percent after the developer announced that preliminary data from an early-stage trial demonstrated that its hepatitis C drug was effective on a
Achillion shares rocket up on promising hep C data
Shares of Achillion Pharmaceuticals rocketed up 66 percent in premarket trading as investors rallied to the news that an early-stage trial had delivered proof of concept data for its hepatitis C
Achillion disappoints investors with lackluster IPO
Achillion Pharmaceuticals went public, raising $51.8 million in its IPO. But the results were well below the established price range. The company sold 30 percent of its equity at $11.50 a share
